2015年12月11日 · Using this format, we generated a bispecific antibody, REGN1979, targeting the B cell marker, CD20 and the CD3 component of the T cell receptor, which triggers redirected killing of B cells. In...

2018年12月15日 · REGN1979是一款 抗CD3 × CD20的双特异性全人源IgG4抗体，由Regeneron公司开发。 REGN1979能够同时结合T细胞表面抗原CD3和B细胞肿瘤细胞上的CD20，通过交联免疫细胞和肿瘤细胞，触发特异性的局部T细胞活化，从而对肿瘤细胞发起攻击。 REGN1979与罗氏的双特异性抗体mosunetuzumab展开了直接竞争。 根据Regeneron在2018年美国血液学会 (ASH)年会上公布的结果，5~40mg剂量REGN1979在治疗复发或难治性滤泡性淋 …

2020年9月15日 · Odronextamab （REGN1979）是一款处于临床研究阶段的双特异性单克隆抗体，旨在通过联结并活化细胞毒性T细胞（结合CD3）和淋巴瘤细胞（结合CD20），触发抗肿瘤作用。 其主要用于治疗既往全身治疗后复发或难治的B细胞非霍奇金淋巴瘤（B-NHL）患者。 REGN1979最早在2019年美国血液协会年会上被公众悉知，由美国生物制药公司再生元 （Regeneron）公布了其I期概念验证研究的数据，对两种最常见的NHL——FL和DLBCL的治 …

2020年11月5日 · BACKGROUND: Odronextamab (REGN1979) is a first-in-class, hinge-stabilized, fully human IgG4-based CD3 x CD20 bispecific antibody (bsAb) that has demonstrated encouraging safety, tolerability and preliminary efficacy in a first-in-human study of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). We report updated ...

REGN1979 is an investigational bispecific monoclonal antibody and is designed to trigger tumor killing by binding to both a B-cell tumor protein (CD20) and an immune system T-cell receptor (CD3).

2022年3月31日 · Odronextamab (REGN1979) is a hinge-stabilised CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering T-cell-mediated cytotoxicity independent of T-cell receptor recognition. 6 It is fully human, IgG4-based, and heterodimeric with a common light chain purified by selective protein A chromatography.

2020年11月5日 · Odronextamab (REGN1979) is a first-in-class, hinge-stabilized, fully human IgG4-based bispecific antibody that binds to CD20-expressing cells and CD3 on T cells, targeting CD20+ cells via T-cell- mediated cytotoxicity independent of T-cell receptor recognition.

2019年11月13日 · REGN1979 is a CD20 x CD3 bispecific IgG4 Ab that binds to CD3+ T-cells and CD20+ B-cells, targeting CD20+ tumor cells via T-cell-mediated cytotoxicity. An ongoing Phase 1 study in patients with B-cell malignancies is evaluating the safety, tolerability, and efficacy of REGN1979 as monotherapy (NCT02290951).

2020年11月5日 · Odronextamab (REGN1979) is a first-in-class, hinge-stabilized, fully human IgG4-based bispecific antibody that binds to CD20-expressing cells and CD3 on T cells, targeting CD20+ cells via T-cell-mediated cytotoxicity independent of T-cell receptor recognition.

2018年11月29日 · REGN1979 is an anti-CD20 x anti-CD3 bispecific IgG4 antibody (Ab) modified to reduce Fc binding. Engaging both targets results in CD20-specific, local T-cell activation and cytotoxicity, a mechanism of action distinct from standard anti-CD20 Abs.